Log In
BCIQ
Print this Print this
 

GX-H9

  Manage Alerts
Collapse Summary General Information
Company Genexine Inc.
DescriptionLong-acting recombinant human growth hormone (rhGH) fused to a hybrid Fc
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase II
Standard IndicationGrowth hormone deficiency
Indication DetailsTreat adult growth hormone deficiency; Treat growth hormone deficiency; Treat pediatric growth hormone deficiency
Regulatory Designation U.S. - Orphan Drug (Treat adult growth hormone deficiency)
PartnerHandok Inc.;
Tasly Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$80.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/19/2015

Undisclosed

Undisclosed

$80.0M

Get a free BioCentury trial today